Emerging reports show that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection precedes the appearance of various autoimmune and autoinflammatory diseases, including paediatric inflammatory multisystemic syndrome (PIMS) or multisystem inflammatory syndrome in children (MIS-C), thus adding to the growing mystery… Continue Reading →
Bayesian analysis of publicly available time series of cases and fatalities in different geographical regions of India during April 2020 is reported. It is found that the initial apparent rapid growth in infections could be partly due to confounding factors… Continue Reading →
The first cases of COVID-19, the disease caused by the SARS-CoV-2 virus, were reported in December, 2019 in the city of Wuhan, in the Hubei province of China. It is therefore reasonable to assume that the disease originated in or around Wuhan.
41 cases of COVID-19 were reported to local health authorities in Wuhan, during December 16, 2019 to January, 2020. The clinical features of these patients were reported in this study in the journal Lancet, in February, 2020:
The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.